PE20050420A1 - Fenacilo 2-hidroxi-3-diaminoalcanos - Google Patents
Fenacilo 2-hidroxi-3-diaminoalcanosInfo
- Publication number
- PE20050420A1 PE20050420A1 PE2004000393A PE2004000393A PE20050420A1 PE 20050420 A1 PE20050420 A1 PE 20050420A1 PE 2004000393 A PE2004000393 A PE 2004000393A PE 2004000393 A PE2004000393 A PE 2004000393A PE 20050420 A1 PE20050420 A1 PE 20050420A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hydroxy
- difluorobenzyl
- amino
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Abstract
SE REFIERE A COMPUESTOS DE FENACILO 2-HIDROXI-3-DIAMINOALCANOS DE FORMULA I, DONDE Z ES [C(R4)(R4´)]m-B; m ES 1-3; R4 Y R4´ SON, INDEPENDIENTEMENTE H, ALQUILO(C1-C6), (CH2)0-3(CICLOALQUILO(C3-C7)), -(CH2)(0-3)OH, ENTRE OTROS; B ES ARILO, HETEROARILO O HETEROCICLILO OPCIONALMENTE SUSTITUIDO CON RB; X ES -(C=O)- O -(SO2)-; R1 ES ALQUILO(C1-C10) OPCIONALMENTE SUSTITUIDOS CON HALOGENO, OH, =O, ENTRE OTROS; R2 Y R3 SON H, F, ALQUILO(C1-C6), -(CH2)0-2-R17, ALQUENILO(C2-C6) , O JUNTOS CON EL C AL CUAL SE ADJUNTAN FORMAN UN CARBOCICLO DE 3 A 7 MIEMBROS DONDE UN C PUEDE SER REPLAZADO POR O, S, SO2 O NR7; R15 ES H, ALQUILO(C1-C6), ALCOXI(C1-C6), ALCOXI(C1-C6)ALQUILO(C1-C6), HIDROXIALQUILO(C1-C6), ENTRE OTROS; Rc ES (CH2)0-3-CICLOALQUILO(C3-C8) OPCIONALMENTE SUSTITUIDO POR -R205, -CO2-(ALQUILO(C1-C4)) Y ARILO. SON COMPUESTOS PREFERIDOS: N-((1S,2R)-1-(3,5-DIFLUOROBENCIL)-3-{[(4R)-6-ETIL-2,2-DIOXIDO-3,4-DIHIDRO-1H-ISOTIOCROMEN-4-IL]AMINO}-2-HIDROXIPROPIL)-2-(1H-IMIDAZOL-4-IL)ACETAMIDA, N-((1S,2R)-1-(3,5-DIFLUOROBENCIL)-2-HIDROXI-3-{[(4-NEOPENTIL-1,1'-BIFENIL-2-IL)METIL]AMINO}PROPIL)-2-FENILACETAMIDA, N-((1S,2R)-1-(3,5-DIFLUOROBENCIL)-3-{[(4R)-6-ETIL-2,2-DIOXIDO-3,4-DIHIDRO-1H-ISOTIOCROMEN-4-IL]AMINO}-2-HIDROXIPROPIL)-3-FENILPROPANAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA BETA-SECRETASA Y SON UTILES PARA EL TRATAMIENTO DEL MAL DE ALZHEIMER Y OTRAS ENFERMEDADES CARACTERIZADAS POR LA DEPOSICION DE UN PEPTIDO A BETA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46467603P | 2003-04-21 | 2003-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050420A1 true PE20050420A1 (es) | 2005-06-13 |
Family
ID=33310933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004000393A PE20050420A1 (es) | 2003-04-21 | 2004-04-21 | Fenacilo 2-hidroxi-3-diaminoalcanos |
Country Status (13)
Country | Link |
---|---|
US (2) | US20050054690A1 (es) |
EP (1) | EP1615915A1 (es) |
JP (1) | JP2006524258A (es) |
AR (1) | AR044043A1 (es) |
BR (1) | BRPI0409627A (es) |
CA (1) | CA2522805A1 (es) |
CL (1) | CL2004000848A1 (es) |
MX (1) | MXPA05011203A (es) |
PA (1) | PA8601001A1 (es) |
PE (1) | PE20050420A1 (es) |
TW (1) | TW200505418A (es) |
UY (1) | UY28279A1 (es) |
WO (1) | WO2004094413A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
JP2007522129A (ja) * | 2004-01-21 | 2007-08-09 | エラン ファーマシューティカルズ,インコーポレイテッド | アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法 |
CA2558249A1 (en) * | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors |
JP2007528400A (ja) | 2004-03-09 | 2007-10-11 | エラン ファーマシューティカルズ,インコーポレイテッド | 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬 |
WO2005087714A2 (en) * | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors |
EP1735293A2 (en) * | 2004-03-09 | 2006-12-27 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
EP1773758A1 (en) * | 2004-07-09 | 2007-04-18 | Elan Pharmaceuticals, Inc. | Oxime derivative hydroxyethylamine aspartyl-protease inhibitors |
US7385085B2 (en) | 2004-07-09 | 2008-06-10 | Elan Pharmaceuticals, Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
US20080103176A1 (en) * | 2005-02-14 | 2008-05-01 | Pfizer Inc. | Substituted Hydroxyethylamines |
WO2007047305A1 (en) | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors |
CA2629402C (en) | 2005-11-21 | 2011-07-26 | Amgen Inc. | Beta-secretase modulators and methods of use |
US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
US7838676B2 (en) * | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
CL2008001500A1 (es) | 2007-05-25 | 2008-12-26 | Amgen Inc | Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros. |
EP2167471B1 (en) | 2007-05-25 | 2013-10-16 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
US8426447B2 (en) * | 2008-09-11 | 2013-04-23 | Amgen Inc. | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use |
EP2504330A1 (en) | 2009-11-23 | 2012-10-03 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
US9296698B2 (en) | 2009-11-23 | 2016-03-29 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
CA2788363A1 (en) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
US8883782B2 (en) | 2010-03-15 | 2014-11-11 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
JP5584352B2 (ja) | 2010-03-15 | 2014-09-03 | アムジエン・インコーポレーテツド | β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途 |
EP2673279A1 (en) | 2011-02-07 | 2013-12-18 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
WO2012158550A2 (en) * | 2011-05-13 | 2012-11-22 | Receptos, Inc. | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
WO2013044092A1 (en) | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
CN115215848B (zh) * | 2021-04-20 | 2024-04-19 | 中国药科大学 | 蛋白激酶抑制剂及其衍生物、制备方法、药物组合物和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5190954A (en) * | 1986-12-17 | 1993-03-02 | Glaxo Group Limited | Methods for the treatment of cognitive disorders |
US5912410A (en) * | 1990-06-15 | 1999-06-15 | Scios Inc. | Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease |
WO1991019810A1 (en) * | 1990-06-15 | 1991-12-26 | California Biotechnology Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
JP3510244B2 (ja) * | 1991-01-21 | 2004-03-22 | エラン ファーマシューティカルス,インコーポレイテッド | アルツハイマー病に関するテストおよびモデル |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
WO1993014200A1 (en) * | 1992-01-07 | 1993-07-22 | Tsi Corporation | Transgenic animal models for alzheimer's disease |
US5604102A (en) * | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
CA2174429C (en) * | 1993-10-27 | 2011-08-30 | Lisa C. Mcconlogue | Transgenic animals harboring app allele having swedish mutation |
US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
DE69515465T2 (de) * | 1994-11-04 | 2000-08-03 | Santen Pharmaceutical Co Ltd | Neue hydroxy-substituierte 1,3-dialkyl-harnstoffderivate |
US5744346A (en) * | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
JPH11507538A (ja) * | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
US6191166B1 (en) * | 1997-11-21 | 2001-02-20 | Elan Pharmaceuticals, Inc. | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
CN1217920C (zh) * | 2000-06-30 | 2005-09-07 | 艾兰制药公司 | 治疗早老性痴呆的化合物 |
PE20020276A1 (es) * | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
JP2004535424A (ja) * | 2001-06-11 | 2004-11-25 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用な置換アミノアルコール |
WO2003006021A1 (en) * | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Alpha-hydroxyamide statine derivatives for the treatment of alzh eimer's disease |
BR0211119A (pt) * | 2001-07-11 | 2005-12-13 | Elan Pharm Inc | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto |
WO2003029169A2 (en) * | 2001-10-04 | 2003-04-10 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
AP2004003049A0 (en) * | 2001-11-08 | 2004-06-30 | Elan Pharm Inc | N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives. |
UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
CL2004000849A1 (es) * | 2003-04-21 | 2005-01-28 | Elan Pharmaceuticals Inc Pharm | Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras. |
MXPA06010899A (es) * | 2004-03-25 | 2006-12-15 | Elan Pharm Inc | 1,3-diaminopropanos substituidos con 2-amino y 2-tio. |
-
2004
- 2004-04-21 CL CL200400848A patent/CL2004000848A1/es unknown
- 2004-04-21 MX MXPA05011203A patent/MXPA05011203A/es active IP Right Grant
- 2004-04-21 PE PE2004000393A patent/PE20050420A1/es not_active Application Discontinuation
- 2004-04-21 BR BRPI0409627-4A patent/BRPI0409627A/pt not_active IP Right Cessation
- 2004-04-21 AR ARP040101346A patent/AR044043A1/es unknown
- 2004-04-21 PA PA20048601001A patent/PA8601001A1/es unknown
- 2004-04-21 US US10/828,582 patent/US20050054690A1/en not_active Abandoned
- 2004-04-21 UY UY28279A patent/UY28279A1/es not_active Application Discontinuation
- 2004-04-21 CA CA002522805A patent/CA2522805A1/en not_active Abandoned
- 2004-04-21 TW TW093111149A patent/TW200505418A/zh unknown
- 2004-04-21 EP EP04760106A patent/EP1615915A1/en not_active Withdrawn
- 2004-04-21 JP JP2006513208A patent/JP2006524258A/ja active Pending
- 2004-04-21 WO PCT/US2004/012384 patent/WO2004094413A1/en active Application Filing
-
2007
- 2007-11-21 US US11/943,961 patent/US20080207696A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200505418A (en) | 2005-02-16 |
PA8601001A1 (es) | 2005-02-04 |
WO2004094413A1 (en) | 2004-11-04 |
CA2522805A1 (en) | 2004-11-04 |
CL2004000848A1 (es) | 2005-01-28 |
UY28279A1 (es) | 2004-11-30 |
JP2006524258A (ja) | 2006-10-26 |
MXPA05011203A (es) | 2005-12-15 |
EP1615915A1 (en) | 2006-01-18 |
AR044043A1 (es) | 2005-08-24 |
US20080207696A1 (en) | 2008-08-28 |
BRPI0409627A (pt) | 2006-04-25 |
US20050054690A1 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
PE20050142A1 (es) | 2-hidroxi-3-diaminoalcanos de benzamida | |
PE20040775A1 (es) | DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2 | |
PE20221264A1 (es) | Inhibidores de egfr | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
PE20011119A1 (es) | Composiciones farmaceuticas de agonista/antagonista de estrogenos para el tratamiento de afecciones que responden a un aumento de testosterona | |
UA72917C2 (en) | Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor | |
PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
RU2011114982A (ru) | Модуляторы нмда-рецептора и их применения | |
RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
PE20051046A1 (es) | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina | |
PE20010964A1 (es) | Derivados de tiazolilamida | |
EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
GB9524157D0 (en) | Therapeutic agents | |
HUP0402236A2 (hu) | Heterociklusos vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AR028531A1 (es) | Compuestos organicos | |
PE20040762A1 (es) | Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer | |
RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b | |
PA8581401A1 (es) | Compuestos de imedazopiridina como agonistas del receptor 5-ht4 | |
PE20070069A1 (es) | Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a | |
PE20060457A1 (es) | Derivados de difenil eter como antagonistas de los receptores 5ht2 | |
HUP0203526A2 (hu) | D4-antagonistákként alkalmazható tienoizoxazolil- és tienilpirazolil-fenoxi-helyettesített propilszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |